Filtered By:
Therapy: Antiviral Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 105 results found since Jan 2013.

New approaches to chikungunya virus vaccine development.
Authors: Garcia A, Diego L, Judith B Abstract Chikungunya virus (CHIKV) is a mosquito-borne human pathogen that affects millions of individuals each year by causing non-specific flu-like symptoms, with a characteristic rash accompanied by joint pain that may last for a long time after the resolution of the infection. Despite intense research efforts, no approved vaccine or antiviral therapy is yet available. This review is based on articles retrieved by PubMed and clinical trials since 1980 to present. Virus complexity, protective and non-protective immune responses against the virus, and the most important a new p...
Source: Recent Patents on Inflammation and Allergy Drug Discovery - June 4, 2015 Category: Allergy & Immunology Tags: Recent Pat Inflamm Allergy Drug Discov Source Type: research

Herpes labialis: An Update.
CONCLUSION: For episodic treatment, oral antiviral agents, such as acyclovir (Zovirax), valacyclovir (Valtrex) and famciclovir (Famvir), are superior to topical antiviral therapy. Valacyclovir and famciclovir have greater oral bioavailability and are better absorbed than acyclovir, require less frequent dosing, but are more expensive and are not approved for children. Topical antiviral agents such as 5% acyclovir cream/ointment (Zovirax) ± hydrocortisone (Xerese), 1% penciclovir (Denavir) cream, and 50 mg Buccal Adhesive Tablet (ABT-50 mg) can also be used for episodic treatment of herpes labialis. These topical agents ar...
Source: Recent Patents on Inflammation and Allergy Drug Discovery - October 5, 2017 Category: Allergy & Immunology Tags: Recent Pat Inflamm Allergy Drug Discov Source Type: research

Herpesviruses and the microbiome
The focus of this article will be to examine the role of common herpesviruses as a component of the microbiome of atopic patients and to review clinical observations suggesting that atopic patients might be predisposed to more severe and atypical herpes-related illness because their immune response is biased toward a TH2 cytokine profile. Human populations are infected with 8 herpesviruses, including herpes simplex virus HSV1 and HSV2 (also termed HHV1 and HHV2), varicella zoster virus (VZV or HHV3), EBV (HHV4), cytomegalovirus (HHV5), HHV6, HHV7, and Kaposi sarcoma–associated herpesvirus (termed KSV or HHV8). Herpesviru...
Source: Journal of Allergy and Clinical Immunology - April 22, 2013 Category: Allergy & Immunology Authors: David H. Dreyfus Tags: Rostrum Source Type: research

Oral direct-acting antiviral therapy for hepatitis C virus (HCV) infection in X-linked agammaglobulinemia
Publication date: Available online 17 October 2018Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Hermann M. . Wolf, Martha M. Eibl, Christian J. Müller
Source: The Journal of Allergy and Clinical Immunology: In Practice - October 17, 2018 Category: Allergy & Immunology Source Type: research

Oral direct-acting antiviral therapy for hepatitis C virus infection in X-linked agammaglobulinemia
Publication date: March 2019Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 7, Issue 3Author(s): Hermann M. Wolf, Martha M. Eibl, Christian J. Müller
Source: The Journal of Allergy and Clinical Immunology: In Practice - March 4, 2019 Category: Allergy & Immunology Source Type: research

Changes in PD-1- and CTLA-4-bearing blood lymphocytes in ICU COVID-19 patients treated with Favipiravir/Kaletra or Dexamethasone/Remdesivir: a pilot study
This study evaluated the frequency of whole blood lymphocytes expressing PD-1 and CTLA-4 in COVID-19 patients upon admission to the intensive care unit (ICU) (i.e., severe) or infection ward (i.e., moderate) and after 7 days of antiviral therapy. COVID-19 patients were treated with either favipiravir or Kaletra (FK group, 11 severe and 11 moderate) or dexamethasone plus remdesivir (DR group, 7 severe and 10 moderate) for 7 days in a pilot study. Eight healthy control subjects were also enrolled. The frequency of PD-1+ and CTLA-4+ lymphocytes in whole blood was evaluated by flow cytometry. Patients on DR therapy had shorter...
Source: Iranian Journal of Allergy, Asthma and Immunology - April 1, 2023 Category: Allergy & Immunology Authors: Esmaeil Mortaz Hamidreza Jamaati Neda K Dezfuli Hakime Sheikhzade Seyed MohammadReza Hashemian Neda Dalil Roofchayee Frazaneh Dastan Payam Tabarsi Gert Folkerts Johan Garssen Sharon Mumby Ian M Adcock Source Type: research